Hcw biologics secures $26.25 million non-dilutive financing with asset-backed development loan

Provides funding for buildout of new headquarters and manufacturing facility capital requirements now funded into 2025 miramar, fla., april 27, 2023 (globe newswire) -- hcw biologics inc. (the “company” or “hcw biologics”) (nasdaq: hcwb), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, entered into a $26.25 million development line of credit agreement on april 21, 2023.
HCWB Ratings Summary
HCWB Quant Ranking